AZP 2006

Drug Profile

AZP 2006

Alternative Names: AZP2006

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AlzProtect; INSERM; University of Lille 2
  • Developer AlzProtect
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 22 Jan 2018 AZP 20016 is still in phase I trials for Progressive-supranuclear-palsy (In volunteers) and Alzheimer's-disease (In volunteers) in France (PO)
  • 22 Jan 2018 AlzProtect plans a phase II clinical trial for Progressive-supranuclear-palsy in an unknown country
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top